Quantum BioPharma Signs Agreement for Lucid-MS IND Application
Quantum BioPharma Signs Agreement for Lucid-MS IND Application
Key Takeaways (TLDR)
Quantum BioPharma gains advantage by signing agreement for Lucid-MS IND application, positioning for Phase 2 clinical trial for multiple sclerosis treatment.
Quantum BioPharma partners with global CRO to submit Lucid-MS IND to FDA in Q4 2025, aiming to prevent demyelination in MS and neurodegenerative disorders.
Quantum BioPharma's Lucid-MS therapy could improve lives by halting myelin degradation, offering hope for better treatments in neurodegenerative diseases like MS.
Quantum BioPharma's innovative approach to neuroprotection with Lucid-MS shows promise in addressing the complex mechanisms of multiple sclerosis and other disorders.
Why it Matters
This news is significant as it highlights Quantum BioPharma's progress in developing a novel therapy for multiple sclerosis, addressing a critical need for neuroprotective treatments. The agreement with a contract research organization marks a crucial step towards initiating a Phase 2 clinical trial, potentially offering new hope for patients with MS and other related disorders.
Summary
Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for its lead compound, Lucid-21-302 (Lucid-MS), targeting multiple sclerosis. The IND submission to the FDA is planned for the fourth quarter of 2025 and, if accepted, would enable the company to initiate a Phase 2 clinical trial. Lucid-21-302 is a patented, non-immunomodulatory neuroprotective therapy shown in preclinical studies to prevent demyelination, a key driver of MS and other neurodegenerative disorders.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Signs Agreement for Lucid-MS IND Application.